UY25590A1 - Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos - Google Patents

Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos

Info

Publication number
UY25590A1
UY25590A1 UY25590A UY25590A UY25590A1 UY 25590 A1 UY25590 A1 UY 25590A1 UY 25590 A UY25590 A UY 25590A UY 25590 A UY25590 A UY 25590A UY 25590 A1 UY25590 A1 UY 25590A1
Authority
UY
Uruguay
Prior art keywords
formula
pain
inflammatory
procedure
indole compounds
Prior art date
Application number
UY25590A
Other languages
English (en)
Inventor
Kazunari Nakao
William Stevens Rodney
Kiyoshi Kawamura
Chikara Uchida
Hiroki Koike
Sthephane Caron
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY25590A1 publication Critical patent/UY25590A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Procedimiento para preparar derivados de indol (FÓRMULA I)como agentes farmaceuticos para el tratamiento o alivio del dolor y la inflamación y de otros transtornos asociados con la inflamación, tales como la artritis. Los compuestos de indol de esta invención tienen inhibición de la COX, preferiblemente COX2, por lo que tambien tiene actividad donde este implocada las prostaglandinas como patógenos, aliviando dolor, fiebre, etc. Tambien estan asociados al tratamiento del cáncer de colon,mama, piel, etc. También incluye osteoartritis, pirexia, asma, reabsorción osea, nefrotoxicidad, dolor, cáncer, Alzheimer. Los compuestos de fórmula I, donde z es OH, alcoxi, -NR2R3 o un grupo de fórmula II o III, donde r es 1,2,3,4; Y es un enlace directo, O, S o NR4 y W e OH o NR2R3,Q es fenilo, un grupo aromáticomonocíclico de 5 eslabones o de 6 eslabones, cicloalquilo C3-7, un heterociclo condensado, R1 es H, alquilo o halo, X es halo, alquilo, OH, etc Ejemplo: (2-benzoil-6-cloro-1H-indol-3-il)acetato de etilo
UY25590A 1998-01-05 1999-06-28 Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos UY25590A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9800003 1998-01-05
UY25332A UY25332A1 (es) 1998-01-05 1998-12-31 Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos

Publications (1)

Publication Number Publication Date
UY25590A1 true UY25590A1 (es) 1999-09-27

Family

ID=11004645

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25332A UY25332A1 (es) 1998-01-05 1998-12-31 Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos
UY25590A UY25590A1 (es) 1998-01-05 1999-06-28 Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY25332A UY25332A1 (es) 1998-01-05 1998-12-31 Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgésicos

Country Status (39)

Country Link
US (1) US6608070B1 (es)
EP (1) EP1045833B1 (es)
JP (1) JP3347136B2 (es)
KR (1) KR100404054B1 (es)
CN (1) CN1284064A (es)
AP (1) AP869A (es)
AR (1) AR016977A1 (es)
AT (1) ATE308519T1 (es)
AU (1) AU748107B2 (es)
BG (1) BG104643A (es)
BR (1) BR9813124A (es)
CA (1) CA2316863A1 (es)
CO (1) CO4970807A1 (es)
DE (1) DE69832200T2 (es)
DZ (1) DZ2700A1 (es)
EA (1) EA200000614A1 (es)
ES (1) ES2255190T3 (es)
GT (1) GT199800205A (es)
HN (1) HN1997000098A (es)
HR (1) HRP20000454A2 (es)
HU (1) HUP0102922A3 (es)
ID (1) ID24876A (es)
IL (1) IL136885A0 (es)
IS (1) IS5532A (es)
MA (1) MA24736A1 (es)
NO (1) NO20003451L (es)
OA (1) OA11441A (es)
PA (1) PA8466201A1 (es)
PE (1) PE20000055A1 (es)
PL (1) PL341696A1 (es)
SA (1) SA99191299A (es)
SK (1) SK9912000A3 (es)
TN (1) TNSN99001A1 (es)
TR (1) TR200001906T2 (es)
TW (1) TW436482B (es)
UY (2) UY25332A1 (es)
WO (1) WO1999035130A1 (es)
YU (1) YU41600A (es)
ZA (1) ZA9911B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
ES2182755T3 (es) * 1999-07-02 2003-03-16 Pfizer Compuestos de tetrazolilalquilindol como agentes antiinflamtorios y analgesicos.
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
EP1572678A4 (en) * 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1534305B9 (en) 2003-05-07 2007-03-07 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
JP5343267B2 (ja) 2006-10-17 2013-11-13 スティーフェル・ラボラトリーズ・インコーポレーテッド タラロゾール代謝物
US20120022121A1 (en) * 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
HUE030263T2 (en) * 2010-04-19 2017-04-28 Octeta Therapeutics Llc New synthesis for the preparation of thiazolidinedione compounds
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
ES2547890T3 (es) 2010-07-07 2015-10-09 Ardelyx, Inc. Compuestos y métodos para inhibir el transporte de fosfato
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
PL2603498T3 (pl) 2010-08-10 2017-06-30 Octeta Therapeutics, Llc Nowa synteza związków tiazolidynodionu
MX342289B (es) 2010-08-10 2016-09-23 Metabolic Solutions Dev Company Llc * Sintesis para compuestos de tiazolidindiona.
US10266490B2 (en) * 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
US9808443B1 (en) 2016-11-28 2017-11-07 King Saud University Cyclooxygenase inhibitors
CN111004121A (zh) * 2019-12-09 2020-04-14 南京杰运医药科技有限公司 一种4-烷氧基乙酰乙酸酯类化合物的制备方法
CN112409281B (zh) * 2020-08-20 2022-11-18 上海大学 (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2

Also Published As

Publication number Publication date
SA99191299A (ar) 2005-12-03
DE69832200T2 (de) 2006-04-20
ES2255190T3 (es) 2006-06-16
KR20010033859A (ko) 2001-04-25
CO4970807A1 (es) 2000-11-07
ATE308519T1 (de) 2005-11-15
JP2002500217A (ja) 2002-01-08
NO20003451L (no) 2000-09-01
WO1999035130A1 (en) 1999-07-15
CA2316863A1 (en) 1999-07-15
IS5532A (is) 2000-06-13
ZA9911B (en) 2000-07-04
US6608070B1 (en) 2003-08-19
TW436482B (en) 2001-05-28
BG104643A (bg) 2001-02-28
EP1045833A1 (en) 2000-10-25
UY25332A1 (es) 2001-01-31
NO20003451D0 (no) 2000-07-04
TR200001906T2 (tr) 2001-01-22
BR9813124A (pt) 2000-10-10
ID24876A (id) 2000-08-31
PA8466201A1 (es) 2000-09-29
AU748107B2 (en) 2002-05-30
IL136885A0 (en) 2001-06-14
PE20000055A1 (es) 2000-02-08
YU41600A (sh) 2003-08-29
EP1045833B1 (en) 2005-11-02
DZ2700A1 (fr) 2003-09-01
HUP0102922A2 (hu) 2001-12-28
SK9912000A3 (en) 2001-11-06
HRP20000454A2 (en) 2001-04-30
OA11441A (en) 2004-04-27
AU1500599A (en) 1999-07-26
DE69832200D1 (de) 2005-12-08
AP869A (en) 2000-09-04
HN1997000098A (es) 1998-12-28
EA200000614A1 (ru) 2001-02-26
JP3347136B2 (ja) 2002-11-20
TNSN99001A1 (fr) 2005-11-10
AP9801423A0 (en) 1998-12-31
AR016977A1 (es) 2001-08-01
PL341696A1 (en) 2001-04-23
KR100404054B1 (ko) 2003-11-01
HUP0102922A3 (en) 2003-06-30
MA24736A1 (fr) 1999-10-01
CN1284064A (zh) 2001-02-14
GT199800205A (es) 2000-06-21

Similar Documents

Publication Publication Date Title
UY25590A1 (es) Procedimiento para preparar compuestos de indol 2,3 sustituidos usados como agentes antiinflamatorios y analgesicos
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
BR0212613A (pt) Compostos de indazol substituìdos para o tratamento de inflamação
BR0307796A (pt) Derivados tricìclicos de pirazol para o tratamento de inflamação
AR024944A1 (es) Amidas de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y su preparacion
IS2293B (is) Arýl sambrædd asapólýsýklísk efnasambönd
ES2196377T3 (es) Derivados de naftiridina.
ES2039919T3 (es) Procedimiento de fabricacion y acondicionamiento de un distribuidor de bolsa, sub-acoplamientos y distribuidores correspondientes.
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
SE9903760D0 (sv) New compounds
ATE301460T1 (de) Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält.
PA8508201A1 (es) Derivados de heterociclo-alquilsulfonil pirazolo como agentes anti-inflamatorios/analgesicos
PA8532201A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
ES2068742B1 (es) Nuevos derivados de piridinio.
ATE206926T1 (de) Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne
ES2184880T3 (es) Asociacion hormonal estrogeno-progestageno, su procedimiento de preparacion y su utilizacion en medicamentos.
BR9911250A (pt) Processo para preparação de compostos
PT98773A (pt) Processo para a preparacao de di-hidropirido/4,3-d/pirimidinas substituidas na posicao 4 e de composicoes farmaceuticas analgesicas e antiinflamatorias que as contem
PA8471801A1 (es) Derivados de higromicina a
HUT70757A (en) Pharmaceutical compositions for treating skin disorders
HUP0203118A2 (hu) Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PA8471901A1 (es) Derivados de 2"-desoxi higromicina
UY32230A (es) Difenilureas (omega)-carboxiarilicas sustituidas como inhibidoras de la raf-quinasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110405